BIOGEN INC. — Director's Dealing 2014

Feb 14, 2014

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: BIOGEN IDEC INC. (BIIB)
CIK: 0000875045
Period of Report: 2014-02-12

Reporting Person: Sandrock Alfred (Grp SVP, Chief Medical Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2014-02-12	Common Stock	M	792	—	Acquired	14459	Direct
2014-02-12	Common Stock	F	367	$323.04	Disposed	14092	Direct
2014-02-12	Common Stock	A	7740	—	Acquired	21832	Direct
2014-02-13	Common Stock	S	425	$316.418	Disposed	21407	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2014-02-12	Restricted Stock Unit	$0	M	792	Disposed	2017-02-12	Common Stock (792)	Direct
2014-02-12	Restricted Stock Unit	$0	A	4000	Acquired	2017-02-12	Common Stock (4000)	Direct
2014-02-12	Restricted Stock Unit	$0	A	13340	Acquired	2019-02-12	Common Stock (13340)	Direct

Footnotes

F1: Sale pursuant to a trading plan intended to comply with Rule 10b5-1 of the Securities Exchange Act of 1934.

F2: Full information regarding the number of shares sold at each separate price will be provided upon request by the SEC staff, the issuer, or a security holder of the issuer.

F3: This represents the weighted average price for shares sold at a range between $316.01 (low) and $316.81 (high).

F4: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 150% of the number of shares at target payout. One-fourth of these RSUs are eligible to vest on each of the first four anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen Idec common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the average 60 calendar-day closing stock price ending on the vesting date divided by the average 60 calendar-day closing stock price on the grant date]).

F5: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen Idec common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date]).

F6: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-fourth of these RSUs are eligible to vest each year for four years, beginning two years from the date of grant. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen Idec common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date]).